NRX Pharmaceuticals (NRXP) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed NRX Pharmaceuticals (NRXP) over the past year, gaining 4.9% versus a loss of 19.3%. Over five years, PMVP leads with a -93.8% price change compared with -97.2% for NRXP. NRX Pharmaceuticals is the larger company by market cap ($125.1 million vs $112.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXP | PMVP |
|---|---|---|
| Share price | $2.89 | $1.49 |
| Market cap | $125.12M | $112.51M |
| 1-day change | -0.34% | -0.67% |
| YTD return | +6.64% | +19.20% |
| 1-year return | -19.27% | +4.93% |
| 5-year return | -97.18% | -93.78% |
| EPS (TTM) | $-0.58 | $-1.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.06 | $1.91 |
| 52-week low | $1.62 | $1.02 |
| Distance from 52-week high | -42.83% | -21.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1232.18% | +181.88% |
| Average volume | 865.49K | 661.39K |
| Shares outstanding | 43.30M | 75.51M |
| Employees | 29 | 54 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed NRXP by 24.2 percentage points over the past year.
- The two companies sit in different sectors: NRX Pharmaceuticals in Health Care and PMV Pharmaceuticals in Healthcare.
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Healthcare · Biotechnology · 54 employees
NRXP vs PMVP FAQ
Which is bigger, NRX Pharmaceuticals or PMV Pharmaceuticals?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $125.12M compared with $112.51M for PMV Pharmaceuticals (PMVP).
Which stock has performed better over the past year, NRXP or PMVP?
PMVP returned +4.93% over the past 12 months, compared with -19.27% for NRXP (price return, excluding dividends). Past performance does not predict future results.
Are NRX Pharmaceuticals and PMV Pharmaceuticals in the same industry?
No. NRX Pharmaceuticals is in the Health Care sector, while PMV Pharmaceuticals is in Healthcare.